Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2014

View Archived Issues

Heptares achieves research milestone in antibody collaboration with MedImmune

Johnson & Johnson reports regulatory news of fourth quarter 2013

Identification of RNA transcription enzyme repressors as novel anticancer drugs

Dendrimer-enhanced docetaxel clinical trial to begin in patients with solid tumors

Amgen reports topline data from phase III GAUSS-2 trial

Kancera to develop a vaccine against ROR to prevent cancer relapse

BioLineRx receives FDA orphan drug designation for stem cell mobilization therapy

California Stem Cell submits phase II trial protocol to FDA for Ovapuldencel-T

Pfizer reports topline results from phase III study of ALO-02

CytRx begins phase II trial of aldoxorubicin for AIDS-related Kaposi's sarcoma

DiaGenic reports final results from exploratory study of blood test for Alzheimer's disease

MDxHealth and Teva Pharmaceuticals sign agreement to commercialize two cancer tests in Israel

Japanese researchers present novel GSK-3 inhibitors for cancer

Roche discloses new agents for HCV infection

FDA grants orphan drug status to Aeolus' drug candidate for treatment of acute radiation syndrome

Novel fatty acid synthase inhibitors patented by GlaxoSmithKline

Novel PCSK9 inhibitors designed by Cadila Healthcare for dyslipidemia

Isis Innovation divulges new RNA polymerase inhibitors for infections

Novartis to request re-examination of E.U. filing for serelaxin

EMA committee recommends approval of Xolair in new indication

Endo and BioDelivery report results from phase III trial of BEMA buprenorphine in chronic pain

Valeant completes acquisition of Solta Medical

KIF20A-derived peptide plus gemcitabine evaluated in pancreatic cancer trial

Previously identified RIP1 kinase inhibitor potentially useful for necroptosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...